MSN: Gen Z grads expect a six-figure starting salary—these are the top 10 jobs that actually pay over $100,000
Gen Z grads expect a six-figure starting salary—these are the top 10 jobs that actually pay over $100,000
These 11 overlooked jobs pay well above average and are actively hiring. Here's what these lesser-known jobs pay and what you'd actually do in each role.
After owning 4 SG's in my life and selling them all, I once again have a hankering to own one. Of the 4, 2 had ebony fingerboards...A '73 Standard and one of those tomato soup "Platinum" Guitar Center specials. That was actually my favorite SG of all but it developed a bad neck crack so Gibson...
MSN: 5 stressful jobs that pay six figures — are they worth it?
Many people think that life gets easier as you make more money, and while that can be true in some contexts, higher earnings can also create new stressors. Sometimes, even the jobs themselves that ...
5 stressful jobs that pay six figures — are they worth it?
Gen Z graduates expect to make $101,500 out the gate—yet workers who recently finished college only took home $68,400 on average, according to a ZipRecruiter report. Here are the jobs where they can ...
AOL: 10 New-Collar Jobs That Pay Six Figures Without a College Degree
The current state of the job market is dismal, to put it mildly. Either AI is coming for your job, the position you actually want demands a bachelor’s degree you don’t have, or it pays so little you’d ...
AOL: 11 Obscure Jobs That Pay Well And Are Desperate For Applicants
Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.
Healio: Mepolizumab safety profile comparable with placebo across 32 studies, multiple indications
Yahoo Finance: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Nasdaq: Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission
Absence of neurotoxicity of any grade in low-volume disease to-date highlights a significant safety profile for NXC-201, which is crucial for patient acceptance and regulatory approval. Company is on ...
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission
The 5-year “real-world” safety profile of esketamine nasal spray for depression was consistent with prior clinical trial data, with most adverse events (AEs) being transient and serious AEs observed ...
MADRID — Real-world data on tirzepatide (Eli Lilly and Company) from a large population database suggest a safety profile of the drug consistent with that in clinical trials and similar to that of ...
The American Journal of Managed Care: Zanubrutinib's Safety Profile in CLL Reinforced in 5-Year Follow-Up of SEQUOIA
The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred ...
World Socialist Web Site: Massive study confirms safety profile of COVID-19 vaccines
A study on 93 million individuals worldwide who received one of the major COVID-19 vaccines confirmed existing knowledge about the safety profile of these vaccines. Adverse events of special interest ...
ascopubs.org: Comparative safety profiles of lutetium-177 and enzalutamide: A pharmacovigilance study and disproportionality analysis using real world data.
Comparative safety profiles of lutetium-177 and enzalutamide: A pharmacovigilance study and disproportionality analysis using real world data.
Seeking Alpha: Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
PharmiWeb: ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis
ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis
Nasdaq: Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile
Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile
Online Recruitment: AI-related jobs are on the rise: What will the future of job profiles look like?
AI-related jobs are on the rise: What will the future of job profiles look like?
Four Futures for Jobs in the New Economy: AI and Talent in 2030 explores how AI advancement and talent trends, and their potential trajectories until 2030, could transform the future of jobs and the global economy. The paper consolidates views and insights from chief strategy officers and other experts around cross-cutting risks and opportunities, and “no-regret” strategies to help leaders ...
Four Futures for Jobs in the New Economy: AI and Talent in 2030
Technological change, geoeconomic fragmentation, economic uncertainty, demographic shifts and the green transition – individually and in combination are among the major drivers expected to shape and transform the global labour market by 2030. The Future of Jobs Report 2025 brings together the perspective of over 1,000 leading global employers—collectively representing more than 14 million ...
Jobs and skills profiles are being transformed by frontier technologies, with businesses aiming to improve their productivity and competitiveness. Yet, this transformation is happening in a macro context of geoeconomic volatility that creates uncertainty for businesses' strategies and talent management.
When the Future of Jobs Report was first published in 2016, surveyed employers expected that 35% of workers’ skills would face disruption in the coming years. The COVID-19 pandemic, along with rapid advancements in frontier technologies, led to significant disruptions in working life and skills, prompting respondents to predict high levels of skills instability in subsequent editions of the ...